Stockscreener 앱 받기
11.12
1.55%
0.17
시간 외 거래:
11.12
전일 마감가:
$10.95
열려 있는:
$10.85
하루 거래량:
454.62K
Relative Volume:
1.11
시가총액:
$219.26M
수익:
$244.06M
순이익/손실:
$87.01M
주가수익비율:
6.1055
EPS:
1.8213
순현금흐름:
$105.95M
1주 성능:
+1.18%
1개월 성능:
-32.81%
6개월 성능:
-28.53%
1년 성능:
-2.63%
1일 변동 폭
$10.57
$11.14
1주일 범위
$10.57
$11.41
52주 변동 폭
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.12 | 215.91M | 244.06M | 87.01M | 105.95M | 1.8213 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Can Keros Therapeutics Rinvatercept stand out in the DMD market? - MSN
Targets Report: Is Keros Therapeutics Inc likely to announce a buyback2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
KROS: Does the Discounted Book Value Represent a Value Trap? - Bitget
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026 - sharewise.com
KROS Stock: Key Information on Rinvatercept for DMD - Bitget
KROS Pipeline Catalysts: DMD Phase II Progress and ALS Strategy for 2026 - Bitget
KROS PE Ratio & Valuation, Is KROS Overvalued - Intellectia AI
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Gains Market Attention In Nasdaq Index - Kalkine Media
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart
Myelofibrosis Market: Strong Pharma Growth Forecast Through - openPR.com
Keros Therapeutics (KROS) director submits initial Form 3 ownership - Stock Titan
Director adds Keros Therapeutics (NASDAQ: KROS) shares under 10b5-1 plan - Stock Titan
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Analysts’ Top Healthcare Picks: Keros Therapeutics (KROS), HeartFlow, Inc. (HTFL) - The Globe and Mail
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Keros (NASDAQ: KROS) moves rinvatercept toward Phase 2 in ALS, DMD - Stock Titan
Keros Therapeutics Presents Additional Clinical Data from - GlobeNewswire
Experimental drug boosts muscle and bone in early trial, eyed for DMD and ALS - Stock Titan
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Keros Therapeutics, Inc. (KROS) reports Q4 loss, misses revenue estimates - MSN
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget
What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - MarketBeat
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):